Wed. 28 Feb 2024, 3:12am ET
Benzinga
News
- Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential
- Includes Future Optionality to Expand Collaboration With Additional Innovative Assets
- Combines Viatris' Financial Strength and Worldwide Operational Infrastructure With Idorsia's Proven, Highly Productive Drug Development Team and Innovation Engine
- Deal Structure Reinforces Viatris' Disciplined Approach to Capital Allocation
- Viatris Announces R&D Event to be Held March 27, 2024